Canada-based DiagnaMed plans to commercially roll out its AI brain health platform, CERVAI, in Q4 2023 as the company announced that the platform entered its final development stage.

CERVAI provides a two-pronged analysis of brain health. The Brain Age Estimation tool uses an electroencephalogram (EEG) headset and a machine learning model to predict brain age.

In a sponsored study at Drexel University in Pennsylvania, US, the software correctly predicted the chronological ages of participants with a medium-to-strong statistical effect.

DiagnaMed says the next step is to have participants use the headset at home to test the technology’s robustness in various settings.

According to the Toronto-based company, the software can be used to reveal whether an individual’s brain is ageing at a faster rate than their actual age – the so-called ‘brain age gap.’

The Brain Health Assessment tool provides insights using OpenAI’s chat GPT to create a personalised medicine approach. The software uses input from self-report or clinician-observed measures to evaluate overall brain health.

DiagnaMed is aiming for late 2023 to deploy its brain-age estimation system. The company is targeting organisations that are interested in tracking age-related brain health – physician’s practices, wellness clinics, and airline products are singled out by the company as potential third-party site hosts of its software.

According to the US Food and Drug Administration's (FDA) database, this product is not yet FDA-registered as of June 2023.

DiagnaMed chairman and CEO Fabio Chianelli said: “We are excited about the development progress we have made with CERVAI, our proprietary generative AI brain health platform, and we expect to have our initial commercial launch for clinic or at-home use in Q4-2023.”

“We expect CERVAI to be a practical tool for the millions of people with mental illness and neurodegenerative diseases.”